Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 28;15(11):1339.
doi: 10.3390/ph15111339.

Recent Advances in Hepatocellular Carcinoma Treatment with Radionuclides

Ruiqi Liu  1 , Hong Li  1 , Yihua Qiu  1 , Hongguang Liu  1 , Zhen Cheng  2   3
Affiliations
Review

Recent Advances in Hepatocellular Carcinoma Treatment with Radionuclides

Ruiqi Liu et al. Pharmaceuticals (Basel). .

Abstract

As the third leading cause of cancer death worldwide, hepatocellular carcinoma (HCC) is characterized by late detection, difficult diagnosis and treatment, rapid progression, and poor prognosis. Current treatments for liver cancer include surgical resection, radiofrequency ablation, liver transplantation, chemotherapy, external radiation therapy, and internal radionuclide therapy. Radionuclide therapy is the use of high-energy radiation emitted by radionuclides to eradicate tumor cells, thus achieving the therapeutic effect. Recently, with the continuous development of biomedical technology, the application of radionuclides in treatment of HCC has progressed steadily. This review focuses on three types of radionuclide-based treatment regimens, including transarterial radioembolization (TARE), radioactive seed implantation, and radioimmunotherapy. Their research progress and clinical applications are summarized. The advantages, limitations, and clinical potential of radionuclide treatment of HCC are discussed.

Keywords: hepatocellular carcinoma; radioactive seed implantation; radioimmunotherapy; transarterial radioembolization.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest, financial or otherwise.

Figures

Figure 1
Figure 1
Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of HCC. (A) Disease-free survival of patients in the 2 treatment groups (p < 0.02). (B) Overall survival of patients in the 2 treatment groups (p < 0.02). Adapted with permission from [32].
Figure 2
Figure 2
Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma. (A) TTP (with progression defined according to RECIST with the recent NCI amendments) in 76 of 108 HCC patients treated by Y-90 glass microsphere radioembolization for which radiological response data were available. The solid line displays the Kaplan–Meier estimator, with marks representing censored events. The shaded area marks the limits of the pointwise 95% CIs. (B) Overall survival in 108 HCC patients treated by Y-90 glass microsphere radioembolization. The solid line displays the Kaplan–Meier estimator, with marks representing censored events. The shaded area marks the limits of the pointwise 95% CIs. Adapted with permission from [48].
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Gans J.H., Lipman J., Golowa Y., Kinkhabwala M., Kaubisch A. Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in? Semin. Nucl. Med. 2019;49:170–181. doi: 10.1053/j.semnuclmed.2019.01.001. - DOI - PubMed
    1. Lafaro K.J., Demirjian A.N., Pawlik T.M. Epidemiology of Hepatocellular Carcinoma. Surg. Oncol. Clin. North Am. 2015;24:1–17. doi: 10.1016/j.soc.2014.09.001. - DOI - PubMed
    1. Moradpour D., Blum H.E. Pathogenesis of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 2005;17:477–483. doi: 10.1097/00042737-200505000-00002. - DOI - PubMed
    1. Magnussen A., Parsi M.A. Aflatoxins, hepatocellular carcinoma and public health. World J. Gastroenterol. 2013;19:1508–1512. doi: 10.3748/wjg.v19.i10.1508. - DOI - PMC - PubMed
    1. Tang W., Chen Z., Zhang W., Cheng Y., Zhang B., Wu F., Wang Q., Wang S., Rong D., Reiter F.P., et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: Theoretical basis and therapeutic aspects. Signal Transduct. Target. Ther. 2020;5:87. doi: 10.1038/s41392-020-0187-x. - DOI - PMC - PubMed